HOPE Therapeutics, Inc., a wholly-owned subsidiary of NRx Pharmaceuticals, Inc., announced the signing of a definitive agreement to purchase the Kadima Neuropsychiatry Institute. Kadima is expected to serve as the clinical model for treatment offerings in HOPE-acquired clinics and a leading investigative site for neuroplastic therapies.
Kadima is recognized as one of California's flagship interventional psychiatry clinics, pioneering ketamine treatment for CNS disorders in a clinical setting. The clinic offers a full range of treatments for suicidal depression, PTSD, and other CNS disorders, including ketamine, Spravato, and transcranial magnetic stimulation (TMS).
Dr. David Feifel, Kadima's founder and Medical Director, will join HOPE as its first Chief Medical Innovation Officer upon closing of the acquisition. The clinic is profitable and forecast to continue growth, making this acquisition a foundational element for HOPE's network expansion. The planned acquisition is subject to satisfaction of standard closing conditions and finalization of financing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.